Official websites use. Share sensitive information only on official, secure websites. Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers.
Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H.
Keywords: Gastroesophageal reflux, Helicobacter pylori , Peptic ulcer, Potassium, Proton pump inhibitors.
Gastric acid secretory inhibitors are effective agents in the treatment of gastroesophageal reflux disease GERD , peptic ulcer disease, and Helicobacter pylori infection, and in the prevention of low-dose aspirin LDA or nonsteroidal anti-inflammatory drug NSAID -induced peptic ulcers. Vonoprazan, a first-in-class potassium-competitive acid blocker P-CAB made in Japan, appeared on the market in , and exhibited rapid, strong, and continuous gastric acid suppression.
Revaprazan showed an early effect on acid suppression. Vonoprazan was significantly effective in the treatment of H. It is rapidly absorbed in the small intestine where it accumulated in the canalicular membranes of parietal cells 25 and it shows a greater acid-inhibitory effect than those of esomeprazole and rabeprazole, as observed from the first day of administration.
